HRAS antibody (C-Term)

Catalog No. ABIN655622

Product Details anti-HRAS Antibody

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Binding Specificity: AA 146-176, C-Term

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HRAS antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF)

Predicted Reactivity: C, Rat

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This HRAS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 146-176 amino acids from the C-terminal region of human HRAS.

Clone: RB14565

Isotype: Ig Fraction

Application Details

Application Notes: IF: 1:10~50. WB: 1:1000. WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

Target Details for HRAS

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Alternative Name: HRAS (HRAS Products)

Background: This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.

Molecular Weight: 21298

Gene ID: 3265

NCBI Accession: NP_001123914, NP_005334, NP_789765

UniProt: P01112

Pathways: p53 Signaling, MAPK Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Hepatitis C, Autophagy, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling